NCT01702298View on ClinicalTrials.gov

A Study to Assess the Safety and Tolerability of Sitagliptin/Simvastatin Fixed-dose Combination (FDC) in Participants With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin Monotherapy (MK-0431D-312)

PHASE3CompletedINTERVENTIONAL
Enrollment

42

Participants

Timeline

Start Date

December 7, 2012

Primary Completion Date

May 29, 2013

Study Completion Date

May 29, 2013

Conditions
Type 2 Diabetes Mellitus
Interventions
DRUG

Sitagliptin 100 mg/simvastatin 40 mg FDC

Sitagliptin 100 mg/simvastatin 40 mg FDC tablet administered once daily in the evening for 6 weeks

DRUG

Metformin

Participants will continue pre-study dose of metformin tablet(s) \>=1000 per day

All Listed Sponsors
lead

Merck Sharp & Dohme LLC

INDUSTRY

NCT01702298 - A Study to Assess the Safety and Tolerability of Sitagliptin/Simvastatin Fixed-dose Combination (FDC) in Participants With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin Monotherapy (MK-0431D-312) | Biotech Hunter | Biotech Hunter